SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its fair launch and strong ties to Bitcoin's network, with many highlighting its potential as the top meme coin on Bitcoin. Discussions emphasize its organic growth, community-driven nature, and unique position within the Bitcoin ecosystem. Some users also point to a publicly traded company accumulating a significant position in the token.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock experiences a notable intraday surge, reaching its highest level in seven months, leading to active debate among traders about its future trajectory. Community discussions revolve around potential price targets and whether the current momentum is sustainable, with some pointing to Elon Musk's influence and potential for further gains, while others express concern about valuation and potential for a pullback. Recent news of Nevada DMV approval for robotaxi testing appears to be a catalyst, as well as speculation around potential rate cuts.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending following news of a partnership with OpenAI, restructuring the latter into a for-profit entity, potentially leading to an IPO. The community is discussing the long-term implications of this deal, Microsoft's AI strategy, and potential price targets. Some are also noting an increase in crypto spam within the MSFT message boards.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending due to a massive surge in stock price and volume, fueled by the appointment of a new CEO and founder-backed capital injections. The community is actively discussing a potential short squeeze, with many calling for the stock to reach ambitious price targets. This activity occurs amidst broader discussions about the housing market and potential interest rate cuts.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending due to news of volume shipments of its Nvidia Blackwell Ultra solutions, signaling potential revenue growth. The community is weighing in on whether this justifies analyst earnings revisions and a rerating of the stock. Some investors believe SMCI is undervalued in the AI infrastructure space, while others remain cautious.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI.X is trending as community members discuss its strong community, positive vibes, and potential as the culture coin of this cycle. Conversations highlight the coin's solid DCA culture and anticipation for a meme super cycle, with some drawing comparisons to early SHIB.X.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu ($BIDU) is trending amid discussions around its AI initiatives and potential for growth beyond its core advertising business, as the company is set to release earnings. While some express concerns about ad revenue, others are optimistic about Baidu's AI cloud and robotaxi ventures. Community members are closely watching for a breakout and debating whether the stock is undervalued or a value trap.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid community discussion around the motives behind the shooting of Charlie Kirk, a prominent conservative figure, with some users speculating about political motivations and potential impacts on free speech. The conversation also involves broader political commentary, including criticism of both Trump's policies and the left-leaning political figures, as well as the potential release of the Epstein files. This situation unfolds within the context of heightened political tensions and renewed debates about extremism and censorship.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

$DEGEN.X is trending as the community discusses its potential for significant gains and upcoming developments. Some investors are excited about a potential Binance listing and the launch of the Degen app, viewing these as catalysts for a substantial price increase. Others in the community are talking about the token burn and participating by voting on X.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid reports of a potential acquisition bid by Paramount Skydance, sending the stock to a multi-year high. The community is buzzing about the possibility of a merger uniting major entertainment brands and streaming services, with some speculating on the offer price and potential for a bidding war. This news arrives as WBD plans to split into two separate entities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) demonstrated improvement in lung function relative to placebo.The late-stage study enrolled 597 patients across multiple locations, and Tyvaso demonstrated superiority over placebo in terms of the change in absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients with IPF. Absolute forced vital capacity (FVC) is a measurement used to gauge lung health, referring to the total volume of air in liters that a person can forcibly exhale after taking a deep, maximum inhalation.Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown cause. It is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. United Therapeutics estimates there are over 100,000 IPF patients in the United States.<a href="https://stocktwits.com/symbol/UTHR">UTHR stock</a> traded nearly 36% higher at the time of writing. On Stocktwits, retail sentiment around the shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume soared from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_12_13_28_PM_png_dae41f310b.webp" alt="UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the positive data implies more funding for more studies.<stembedurl>https://stocktwits.com/DonnyDonowitz/message/627212165</stembedurl>Another user expects the stock to close at $450.<stembedurl>https://stocktwits.com/wallstreet63/message/627228569</stembedurl>United Therapeutics <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.unither.com/press-releases/2025/09-02-2025-120037033">intends</a> to use the data from both the study and an ongoing study of nebulized Tyvaso to support a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to add IPF to the labeled indications for nebulized Tyvaso. Data from the ongoing study is expected in the first half of 2026, and the company plans to meet with the FDA before the end of the year to discuss ways to expedite the review process once the data is in, the company said.Following the announcement, multiple analysts hiked their price target on UTHR.<ul style="list-style-type:square;"><li>BofA raised its price target to $463 from $314 and kept a ‘Neutral’ rating on the shares. The firm said that the results were “surprisingly positive” and added that it expects $2.5 billion risk-adjusted peak sales for the drug in IPF.&nbsp;</li><li>Jefferies analyst Roger Song raised the firm's price target to $564 from $432 while keeping a ‘Buy’ rating on the shares.</li></ul>UTHR stock is up by 17% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-stock-plunges-after-announcing-cost-cutting-measures/chv6vkKRdF3">Why Did Bollinger Innovations Stock Plunge 18% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside

The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial. 

Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y

United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UTHR News

UTHR United Therapeutics Corp